February 14, 2020 Astra turns to bispecifics to solve the treme problem Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
October 09, 2019 SITC 2019 preview – Nextcure’s time to shine The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
